Wilde Brandon M, Hotaling James M, Welt Corrine, Tashjian Robert, Joyce Christopher D, Chalmers Peter N
Department of Orthopaedic Surgery, University of Utah, Salt Lake City, UT, USA.
Department of Urology, University of Utah, Salt Lake City, UT, USA.
JSES Rev Rep Tech. 2025 Mar 9;5(3):407-412. doi: 10.1016/j.xrrt.2025.02.002. eCollection 2025 Aug.
The objective of this study was to determine the acceptability of biologic treatments for patients undergoing rotator cuff repair.
This is a survey-based analysis of treatment acceptability of patients undergoing rotator cuff repair. Preoperatively, we collected demographics and survey responses. Patients were surveyed using a 5-point Likert scale regarding their willingness to undergo variations on biologic treatments for rotator cuff tears. These variations included frequency of treatment (daily, every other day, and weekly); duration of treatment (1, 3, and 6 months); side effect frequency (10%, 25%, 50%, and 75%); efficacy in terms of increased success rates (10% more, 20% more, and 30% more); and method of administration (injection, oral, and implantable). Descriptive statistical analysis was performed.
Fifty-five patients responded to the survey. The cohort was 65% male, with a mean ± standard deviation age of 60 ± 11 years, body mass index of 30 ± 7, and Charlson comorbidity index of 2 ± 1. With regards to frequency of treatment, 73% of patients either strongly agreed or agreed that they were willing to take a pill daily if it would increase the likelihood of success. For injections, 80% of patients either strongly agreed or agreed that they were willing to undergo an injection once, 71% weekly, 76% monthly, and 76% every 3 months. With regards to duration, 76% either strongly agreed or agreed that they were willing to take a medication for 1 month, 64% for 3 months, and 55% for 6 months. With regards to side effects, 47% either strongly agreed or agreed that they were willing to undergo a treatment with 10% side effects, 13% with 25% side effects, 7% with 50% side effects, and 7% with 75% side effects. With regards to efficacy, 73% either strongly agreed or agreed that they were willing to undergo a biologic treatment if it increased their success rates by even 10%.
Based upon these survey responses, the biologic treatment options most acceptable to patients would be a pill or injection, administered for up to 3 months after surgery, with fewer than 10% of patients experiencing side effects. Most patients were willing to undergo a biologic treatment even if it only increased their likelihood of success by 10%. Therefore, based on these results, researchers and physicians developing biologic treatments could focus on avenues that only slightly increase success rates and can be administered within 3 months of surgery provided there is a favorable side effect profile.
本研究的目的是确定生物治疗对接受肩袖修复手术患者的可接受性。
这是一项基于调查的对接受肩袖修复手术患者治疗可接受性的分析。术前，我们收集了人口统计学数据和调查回复。使用5分李克特量表对患者进行调查，询问他们接受肩袖撕裂生物治疗不同方案的意愿。这些方案包括治疗频率（每日、隔日和每周）；治疗持续时间（1、3和6个月）；副作用发生率（10%、25%、50%和75%）；成功率提高幅度（提高10%、20%和30%）；以及给药方式（注射、口服和植入）。进行了描述性统计分析。
55名患者回复了调查。该队列中65%为男性，平均年龄±标准差为60±11岁，体重指数为30±7，Charlson合并症指数为2±1。关于治疗频率，73%的患者强烈同意或同意如果每日服药能提高成功几率，他们愿意每日服药。对于注射，80%的患者强烈同意或同意他们愿意接受一次注射，71%愿意每周注射，76%愿意每月注射，76%愿意每3个月注射。关于持续时间，76%的患者强烈同意或同意他们愿意服药1个月，64%愿意服药3个月，55%愿意服药6个月。关于副作用，47%的患者强烈同意或同意他们愿意接受副作用发生率为10%的治疗，13%愿意接受副作用发生率为25%的治疗，7%愿意接受副作用发生率为50%的治疗，7%愿意接受副作用发生率为75%的治疗。关于疗效，73%的患者强烈同意或同意如果生物治疗能将成功率提高哪怕10%，他们愿意接受。
根据这些调查回复，患者最能接受的生物治疗方案是术后服用药丸或注射，持续3个月，副作用发生率低于10%。大多数患者即使生物治疗仅将成功几率提高10%也愿意接受。因此，基于这些结果，研发生物治疗的研究人员和医生可以专注于那些仅略微提高成功率且在术后3个月内给药且副作用情况良好的途径。
